Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

J Jendle; M A Nauck; D R Matthews; A Frid; K Hermansen; M During; M Zdravkovic; Boyd Josef Gimnicher Strauss; A J Garber

doi:10.1111/j.1463-1326.2009.01158.x

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

J Jendle
, M A Nauck
, D R Matthews
, A Frid
, K Hermansen
, M During
, M Zdravkovic
, Boyd Josef Gimnicher Strauss
, A J Garber

Nutrition Dietetics & Food

Research output: Contribution to journal › Article › Research › peer-review

285 Citations (Scopus)

Abstract

The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D

Original language	English
Pages (from-to)	1163 - 1172
Number of pages	10
Journal	Diabetes, Obesity and Metabolism
Volume	11
Issue number	12
DOIs	https://doi.org/10.1111/j.1463-1326.2009.01158.x
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/j.1463-1326.2009.01158.x

Cite this

Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., During, M., Zdravkovic, M., Strauss, B. J. G., & Garber, A. J. (2009). Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity and Metabolism, 11(12), 1163 - 1172. https://doi.org/10.1111/j.1463-1326.2009.01158.x

@article{852a8a386ef842a6b82a0eb1ccb95c0a,

title = "Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue",

abstract = "The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D",

author = "J Jendle and Nauck, \{M A\} and Matthews, \{D R\} and A Frid and K Hermansen and M During and M Zdravkovic and Strauss, \{Boyd Josef Gimnicher\} and Garber, \{A J\}",

year = "2009",

doi = "10.1111/j.1463-1326.2009.01158.x",

language = "English",

volume = "11",

pages = "1163 -- 1172",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "12",

}

Jendle, J, Nauck, MA, Matthews, DR, Frid, A, Hermansen, K, During, M, Zdravkovic, M, Strauss, BJG & Garber, AJ 2009, 'Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue', Diabetes, Obesity and Metabolism, vol. 11, no. 12, pp. 1163 - 1172. https://doi.org/10.1111/j.1463-1326.2009.01158.x

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. / Jendle, J; Nauck, M A; Matthews, D R et al.
In: Diabetes, Obesity and Metabolism, Vol. 11, No. 12, 2009, p. 1163 - 1172.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

AU - Jendle, J

AU - Nauck, M A

AU - Matthews, D R

AU - Frid, A

AU - Hermansen, K

AU - During, M

AU - Zdravkovic, M

AU - Strauss, Boyd Josef Gimnicher

AU - Garber, A J

PY - 2009

Y1 - 2009

N2 - The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D

AB - The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D

UR - http://www3.interscience.wiley.com/cgi-bin/fulltext/122604733/HTMLSTART

U2 - 10.1111/j.1463-1326.2009.01158.x

DO - 10.1111/j.1463-1326.2009.01158.x

M3 - Article

SN - 1462-8902

VL - 11

SP - 1163

EP - 1172

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 12

ER -

Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, During M et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity and Metabolism. 2009;11(12):1163 - 1172. doi: 10.1111/j.1463-1326.2009.01158.x

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Abstract

UN SDGs

Access to Document

Other files and links

Cite this